Last $3.29 USD
Change Today +0.01 / 0.30%
Volume 309.5K
As of 8:10 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

ziopharm oncology inc (ZIOP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - $5.58
52 Week Low
05/9/14 - $2.87
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZIOPHARM ONCOLOGY INC (ZIOP)

ziopharm oncology inc (ZIOP) Related Bloomberg News

View More Bloomberg News

ziopharm oncology inc (ZIOP) Related Businessweek News

No Related Businessweek News Found

ziopharm oncology inc (ZIOP) Details

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the discovery and development of cancer therapies that address unmet medical needs through synthetic biology. The company is employing novel gene expression and control technology to deliver DNA for the treatment of cancer. Its technology platform employs Intrexon Corporation’s RheoSwitch Therapeutic System platform to turn on and off, and modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is being evaluated in Phase II clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The company is also developing novel small molecules as potential cancer therapeutics. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

43 Employees
Last Reported Date: 03/3/14

ziopharm oncology inc (ZIOP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $230.3K
President of Research & Development and Chief...
Total Annual Compensation: $121.9K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $411.3K
Total Annual Compensation: $206.3K
Compensation as of Fiscal Year 2013.

ziopharm oncology inc (ZIOP) Key Developments

ZIOPHARM Oncology, Inc. Reports Unaudited Earnings Results for the Second Quarter Ended June 30, 2014

ZIOPHARM Oncology, Inc. reported unaudited earnings results for the second quarter ended June 30, 2014. For the quarter, the company’s revenue was $200,000 against $200,000 a year ago. Loss from operations was $11,177,000 against $18,296,000 a year ago. Net loss was $5,576,000 against $18,692,000 a year ago. Basic and diluted net loss per share was $0.06 against $0.22 a year ago.

ZIOPHARM Oncology and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin

ZIOPHARM Oncology, Inc. announced an amendment and restatement of their License and Collaboration Agreement for darinaparsin and related organoarsenic molecules. Under the terms of the amended and restated agreement, ZIOPHARM granted Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, ZIOPHARM will be eligible to receive from Solasia up to $72.2 million in development and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin.

ZIOPHARM Oncology, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 10:00 AM

ZIOPHARM Oncology, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 10:00 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Francois Lebel, Senior Vice President of Clinical Development and Medical Operations, Jonathan J. Lewis, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $3.29 USD +0.01

ZIOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $3.74 USD +0.01
Genocea Biosciences Inc $12.70 USD -0.44
View Industry Companies

Industry Analysis


Industry Average

Valuation ZIOP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 411.7x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 346.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at